Walleye Trading LLC Viking Therapeutics, Inc. Call Options Transaction History

Walleye Trading LLC

$41.2 Billion
Q2 2024

Call Options

17 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $303,296 - $513,280	-6,400 Reduced 72.73%	2,400 $127,000
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $481,979 - $2.62 Million	-27,700 Reduced 75.89%	8,800 $721,000
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $175,560 - $373,160	19,000 Added 108.57%	36,500 $679,000
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $110,292 - $161,600	10,100 Added 136.49%	17,500 $193,000
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $41,552 - $69,412	2,800 Added 60.87%	7,400 $119,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $201,192 - $431,516	-24,900 Reduced 84.41%	4,600 $76,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $80,240 - $277,300	29,500 New	29,500 $277,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $106,000 - $134,200	-20,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $22,920 - $32,439	-4,000 Reduced 16.67%	20,000 $116,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $57,854 - $107,464	13,300 Added 124.3%	24,000 $173,000
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $570,630 - $1.31 Million	-165,400 Reduced 93.92%	10,700 $50,000
Q4 2019 Feb 14, 2020	BUY	$6.38 - $8.73 $1.12 Million - $1.54 Million	176,100 New	176,100 $1.41 Million
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $575,745 - $755,940	-87,900 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $804,583 - $1.12 Million	-104,900 Reduced 54.41%	87,900 $730,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $750,420 - $984,060	99,000 Added 105.54%	192,800 $1.92 Million
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $655,856 - $1.48 Million	91,600 Added 4163.64%	93,800 $718,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $21,340 - $43,230	2,200 New	2,200 $38,000

Others Institutions Holding VKTX

# of Institutions

480

Shares Held

66.2M

Call Options Held

6.24M

Put Options Held

3.01M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.

Account